PT800399E - Tratamento terapeutico combinado de patologias hiperproliferativas - Google Patents

Tratamento terapeutico combinado de patologias hiperproliferativas

Info

Publication number
PT800399E
PT800399E PT96901387T PT96901387T PT800399E PT 800399 E PT800399 E PT 800399E PT 96901387 T PT96901387 T PT 96901387T PT 96901387 T PT96901387 T PT 96901387T PT 800399 E PT800399 E PT 800399E
Authority
PT
Portugal
Prior art keywords
therapeutic treatment
combined therapeutic
hyperproliferative pathologies
hyperproliferative
pathologies
Prior art date
Application number
PT96901387T
Other languages
English (en)
Inventor
Bruno Tocque
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PT800399E publication Critical patent/PT800399E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT96901387T 1995-01-17 1996-01-12 Tratamento terapeutico combinado de patologias hiperproliferativas PT800399E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9500436A FR2729295A1 (fr) 1995-01-17 1995-01-17 Traitement therapeutique combine des pathologies hyperproliferatives

Publications (1)

Publication Number Publication Date
PT800399E true PT800399E (pt) 2002-12-31

Family

ID=9475169

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96901387T PT800399E (pt) 1995-01-17 1996-01-12 Tratamento terapeutico combinado de patologias hiperproliferativas

Country Status (21)

Country Link
US (3) US6262032B1 (pt)
EP (1) EP0800399B1 (pt)
JP (3) JP4580469B2 (pt)
KR (1) KR100385266B1 (pt)
AT (1) ATE222109T1 (pt)
AU (1) AU716364B2 (pt)
BR (1) BR9606969A (pt)
CA (1) CA2209771C (pt)
CZ (1) CZ298710B6 (pt)
DE (1) DE69622989T2 (pt)
DK (1) DK0800399T3 (pt)
ES (1) ES2180729T3 (pt)
FI (1) FI119911B (pt)
FR (1) FR2729295A1 (pt)
HU (1) HU229484B1 (pt)
MX (1) MX9704490A (pt)
NO (1) NO325418B1 (pt)
PT (1) PT800399E (pt)
SI (1) SI0800399T1 (pt)
SK (1) SK283989B6 (pt)
WO (1) WO1996022101A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044396A1 (en) * 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
ES2236481T3 (es) 2001-01-16 2005-07-16 Glaxo Group Limited Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
ES2308200T3 (es) * 2003-06-30 2008-12-01 Universite De Lausanne Peptido derivado de rasgap para destruir selectivamente celulas cancerosas.
AU2004305386A1 (en) * 2003-12-24 2005-07-07 Locomogene, Inc. Method of suppressing cancer
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
WO2008115478A2 (en) * 2007-03-19 2008-09-25 University Of Medicine And Dentistry Of New Jersey Method of cancer detection and treatment
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274482B2 (en) * 1986-03-28 2003-03-12 The Board Of Trustees Of The University Of Illinois Isolated dna sequences associated with multidrug resistance in human cells
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2136091A1 (en) * 1992-05-20 1993-11-25 Daniel S. Martin Chemotherapeutic drug combinations
WO1993024096A2 (en) * 1992-05-28 1993-12-09 Xenova Limited Use of n-(2-(dimethylamino)ethyl)acridine-4-carboxamide and its analogues for cancer treatment
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
EP0672137A1 (en) * 1992-09-18 1995-09-20 CANJI, Inc. Gene therapy by retroviral vector with tumor suppressive gene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6054467A (en) 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis

Also Published As

Publication number Publication date
DE69622989T2 (de) 2002-12-05
JP4580469B2 (ja) 2010-11-10
FI973023A (fi) 1997-07-16
SI0800399T1 (en) 2002-12-31
WO1996022101A1 (fr) 1996-07-25
JP2012036201A (ja) 2012-02-23
CA2209771C (fr) 2012-01-03
JPH10512559A (ja) 1998-12-02
FR2729295A1 (fr) 1996-07-19
NO973197D0 (no) 1997-07-09
HUP9802423A3 (en) 2000-11-28
DK0800399T3 (da) 2002-12-02
FI119911B (fi) 2009-05-15
HUP9802423A2 (hu) 1999-02-01
NO973197L (no) 1997-07-09
AU716364B2 (en) 2000-02-24
NO325418B1 (no) 2008-04-21
KR19980701449A (ko) 1998-05-15
DE69622989D1 (de) 2002-09-19
ES2180729T3 (es) 2003-02-16
FR2729295B1 (pt) 1997-02-28
HU229484B1 (en) 2014-01-28
JP5031921B2 (ja) 2012-09-26
EP0800399B1 (fr) 2002-08-14
FI973023A0 (fi) 1997-07-16
CZ298710B6 (cs) 2008-01-02
US7884082B2 (en) 2011-02-08
JP2008133291A (ja) 2008-06-12
AU4542996A (en) 1996-08-07
CZ226297A3 (en) 1997-10-15
ATE222109T1 (de) 2002-08-15
US20010021395A1 (en) 2001-09-13
CA2209771A1 (fr) 1996-07-25
US20040127437A1 (en) 2004-07-01
SK95797A3 (en) 1997-12-10
MX9704490A (es) 1997-10-31
BR9606969A (pt) 1997-11-04
KR100385266B1 (ko) 2005-09-07
SK283989B6 (sk) 2004-07-07
EP0800399A1 (fr) 1997-10-15
US20050209177A9 (en) 2005-09-22
US6262032B1 (en) 2001-07-17

Similar Documents

Publication Publication Date Title
PT800399E (pt) Tratamento terapeutico combinado de patologias hiperproliferativas
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
DE69600596D1 (de) Zweikammer-schrittmacher-anordnung zur kontinuierlichen regelung des av zeitintervalles mit dem ziel, optimierte stimulierung zur behandlung von kardiomyopathien zu erreichen
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
PL340631A1 (en) Azelaic acid containing composition
IL121272A0 (en) Nucleotide comprising compositions and their use for improving therapeutic index of a therapeutic drug
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
ZA968905B (en) Transdermal therapeutic system (tts) for administering active substances for drug dependence or drug addiction
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
PL336760A1 (en) Treatment of skin diseases
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
IL118218A0 (en) Terpenoidic derivatives and pharmaceutical compositions containing them
MX9803610A (es) Utilizacion de flupirtina para la profilaxis y la terapia de enfermedades que van a compañadas de un deterioro del sistema celular hermatopoyetico.
IL116733A0 (en) The use of sertraline to treat cancer patients
ITRM960096V0 (it) Dispositivo per il trattamento del corpo umano.
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
DE29501910U1 (de) Transdermales therapeutisches den Wirkstoff Dimethisoquin enthaltendes System
TR199801887A2 (xx) Bir Na+/H+ - de�i�tiricisi inhibit�r�.
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
DE69808839T2 (de) Makrophagen-stimulierende Protein für Behandlung von Erkrankungen des Nervensystems
UA22223A (uk) Спосіб лікуваhhя захворюваhь оргаhа зору
ZA897549B (en) Medicament for the treatment of diseases caused by retroviruses